Tengo 21 aos o ms y entiendo que este sitio, sus productos y recursos son solo para fines de investigacin e informacin, no para uso humano o veterinario ni como asesoramiento mdico.
The question is no longer whether scrutiny is coming
Speak with your healthcare provider about the most appropriate support for your individual circumstances
'cause we're looking for long-term relationships
Beginning as early as April 1, 2026, Medicare beneficiaries will pay no more than $50 per month for Lillys Zepbound (tirzepatide), available in a multi-dose pen, and for orforglipron, Lilly's once-daily obesity pill, provided both receive approval from the US Food and Drug Administration (FDA), according to a news release from Lilly
Multi-vial protocols: For longer protocols, you'll use multiple vials